CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?

Abstract Chimeric antigen receptor T (CAR‐T) therapy has emerged as a revolutionary new pillar in cancer care, particularly in relapsed/refractory (r/r) B‐cell malignancies. Following impressive clinical outcomes in hematological malignancies, the FDA‐approved six CAR‐T cell products for indications such as lymphoma, leukemia, and myeloma. Despite the numerous advantages of CAR‐T cell treatment, several challenges exist that interfere with its therapeutic efficacy. Serious adverse effects connected with the treatment continue to be a major concern. In addition, poor persistence of therapeutics and antigen escape frequently result in tumor relapse. Exorbitant treatment cost further remains a significant barrier to its effective implementation, limiting its accessibility. This review presents progress of CAR‐T research, the key obstacles that hamper promising outcomes for patients with hematological malignancies, and a few strategies to overcome them.